Nesina
Nesina

1.08
A generic medicine indicated for diabetes. Promotes the release of insulin and lowers blood glucose levels following meal consumption.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Alogliptin benzoate
Reference Brand
Alogliptin
Product Origin
Generic Alternative
Reference Manufacturer
Takeda
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Antidiabetics
Product Category
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Pharmacological Class
Antidiabetic
Clinical Indications
Manufacturer Description
Indicated to address glucose concentrations to manage type 2 diabetes and alleviate postprandial sugar spikes.
Mechanism of Action
Inhibits DPP-4, preventing degradation of active incretins to trigger insulin release and suppress glucagon output.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Diabetic ketoacidosis, History of severe hypersensitivity to alogliptin
Severe Adverse Events
Acute pancreatitis — requires immediate medical attention, Severe anaphylaxis — requires immediate medical attention
Common Side Effects
Headache, Stuffy nose, Diarrhea
Uncommon Side Effects
Upper respiratory tract infection, Joint pain, Nausea
Drug Interactions
Insulin, Diuretics
Pregnancy Safety Warnings
TGA Category B: Safety confirmed in animal studies. Breastfeeding: Consult a doctor.
Age Restrictions
Approved for adults.
Storage Guidelines
Store below 25°C.
Related Products
Information related to Nesina is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
where to purchase Cancer Treatment Tablets - Cosudex Australia